ArrowheadPharma

@ArrowheadPharma

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Pasadena, CA and Madison, WI
Vrijeme pridruživanja: listopad 2011.

Tweetovi

Blokirali ste korisnika/cu @ArrowheadPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ArrowheadPharma

  1. Today reported promising interim results from ongoing Ph1/2a studies of our cardiometabolic candidates ARO-APOC3 being developed for severe & ARO-ANG3 being developed for & . Learn more:

    Poništi
  2. Today we are hosting a webcast & conference call at 4:30 p.m. EST to discuss our fiscal 2020 Q1 . The live audio webcast can be accessed on our website at . Conference call details can be found here: .

    Poništi
  3. proslijedio/la je Tweet

    Congratulations to and team recruiting UK's 1st patient to the ARO-AAT 2002 Study, investigating a drug to treat disease due to Alpha-1 Antitrypsin Deficiency . More on in Scotland: .

    Poništi
  4. 22. sij

    We will host a webcast and conference call at 4:30 p.m. EST on Wednesday, February 5 to discuss our fiscal 2020 Q1 . See press release for conference call and webcast details:

    Poništi
  5. 6. sij

    We are pleased to welcome James Hassard to the Arrowhead team in the newly-created position of chief commercial officer. Please read the full press release here:

    Poništi
  6. 24. pro 2019.

    Wishing everyone a and a wonderful from the Arrowhead team! We have plenty to look forward to in 2020, including the continued development of our therapies for intractable diseases.

    Poništi
  7. 20. pro 2019.

    We've dosed the first patient in AROAAT002, an open-label Phase 2 clinical study of ARO-AAT, 's second generation therapeutic being developed as a treatment for the rare genetic associated with . Read more details at:

    Poništi
  8. 16. pro 2019.

    Today, we announced filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD, our investigational therapeutic being developed as a treatment for alcohol related & nonalcohol related , such as . Read:

    Poništi
  9. 13. pro 2019.

    We're pleased to welcome Marianne De Backer to 's Board of Directors. is the current Executive VP, Head of Global Business Development & Licensing, and member of the Executive Committee of the Pharmaceuticals division of . Read:

    Poništi
  10. 11. pro 2019.

    Today, we announced submitted an Investigational New Drug () application to the for a Phase 1b adaptive dose-finding clinical study of ARO-HIF2, an investigational therapeutic being developed as a treatment for . Read more here: .

    Poništi
  11. 28. stu 2019.

    Happy Thanksgiving from the team at Arrowhead! Wishing you and your loved ones a joyous and gratitude-filled holiday.

    Poništi
  12. 27. stu 2019.

    It was a pleasure to participate in the 2019 “Virtual Walk for Alpha-1” hosted by . Our team members based in Pasadena, CA and Madison, WI all joined in to raise awareness during month!

    Poništi
  13. 25. stu 2019.

    Today we are hosting a webcast and conference call at 4:30 PM EDT to discuss our fiscal year end . The live audio webcast can be accessed on our website at . Conference call details can be found here:

    Poništi
  14. 25. stu 2019.

    disease is a rare genetic disorder. It can lead to serious including and . Check out ’s resources to help raise :

    Poništi
  15. 20. stu 2019.

    At Arrowhead, we’re developing a potential treatment for the associated with antitrypsin deficiency (). This genetic condition can lead to serious lung disease and/or . Learn more about here:

    Poništi
  16. 18. stu 2019.

    Today, we presented updated Phase 1 clinical data in two late-breaking oral presentations at on our cardiometabolic candidates ARO-APOC3 and ARO-ANG3. Read our press release here: and see presentation slides here:

    Poništi
  17. 15. stu 2019.

    Heartfelt thanks to Dr. Bruce Given for decades of work bringing important new medicines to patients and a sincere welcome to Dr. Javier San Martin and Dr. Curt Bradshaw who share the same passion for innovation

    Poništi
  18. 15. stu 2019.

    November is month. estimates that at least 100,000 people in the U.S. live with deficiency. This rare genetic disorder severely damages the liver and lungs. To help raise , click here:

    Poništi
  19. 11. stu 2019.

    We will host a webcast and conference call at 4:30 PM EDT on Monday, November 25 to discuss our fiscal year end . Please see press release for conference call and webcast details:

    Poništi
  20. 8. stu 2019.

    Today, Arrowhead and collaborator Janssen announced Phase 2 data in two poster presentations at ’s . Read our press release here: and see the posters here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·